Imatinib (Standard)

Overview

Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL , v-Abl , PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-15463R
• CAS No.: 152459-95-5
• Molecular Formula: C29H31N7O
• Molecular Weight: 493.60
• Purity: 99.74%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source